Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buprenorphine
Drug ID BADD_D00310
Description Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction.[F4715,F4718] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,F4715,F4718] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet.
Indications and Usage For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
Marketing Status Prescription; Discontinued
ATC Code N02AE01; N07BC01
DrugBank ID DB00921
KEGG ID D07132
MeSH ID D002047
PubChem ID 644073
TTD Drug ID D06AWE
NDC Product Code 51927-0062; 12578-607; 65724-0050; 0093-3659; 71335-0353; 42858-586; 60687-492; 62756-460; 59011-750; 65267-203; 67509-003; 12496-0100; 60687-481; 42858-353; 69238-1203; 42858-501; 59011-758; 62756-459; 71335-1154; 12496-0300; 69238-1505; 38779-3255; 59011-751; 68071-2592; 59011-757; 50090-5805; 73548-1039; 0093-3657; 0792-0631; 59011-752; 71335-0950; 69238-1202; 69238-1204; 0228-3153; 42858-502; 49812-0239; 0093-3239; 70518-1625; 42858-750; 0093-3658; 42858-493; 42858-839; 71795-2200; 0093-3656; 10920-593; 0228-3156; 12707-036; 47848-030; 69238-1205
Synonyms Buprenorphine | Buprenex | Prefin | Subutex | Buprex | Temgesic | Temgésic | 6029-M | 6029 M | 6029M | RX-6029-M | RX 6029 M | RX6029M | Buprenorphine Hydrochloride | Hydrochloride, Buprenorphine
Chemical Information
Molecular Formula C29H41NO4
CAS Registry Number 52485-79-7
SMILES CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.0020.002788%
Emotional disorder19.04.02.0050.003717%Not Available
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.0060.032524%
Eye pain06.08.03.0020.002788%
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fall12.01.08.002--
Fatigue08.01.01.0020.069695%
Feeling abnormal08.01.09.0140.060403%Not Available
Feeling cold08.01.09.0080.007434%Not Available
Feeling drunk08.01.09.0150.001859%Not Available
Feeling hot08.01.09.0090.006505%Not Available
Feeling jittery08.01.09.0160.005576%Not Available
Flatulence07.01.04.002--
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance17.02.05.016; 08.01.02.002--
Gastrointestinal disorder07.11.01.001--Not Available
Hallucination19.10.02.0020.013010%
Hallucination, auditory19.10.02.0030.001859%Not Available
Head discomfort17.02.05.0270.003717%Not Available
Headache17.14.01.0010.112442%
Heart rate decreased13.14.04.0010.002788%Not Available
Heart rate increased13.14.04.0020.008363%Not Available
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004--Not Available
Hepatitis acute09.01.07.0050.001859%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 11 Pages